Phase 2 Data Shows Maribavir Markedly Reduced Rate Of Cytom

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Stem Cell Research News
Reply to topic
Phase 2 Data Shows Maribavir Markedly Reduced Rate Of Cytom
RSS FEED


Joined: 05 Apr 2006
Posts: 19275
Post Posted: Thu Jun 05, 2008 8:22 am Reply with quote
ViroPharma Incorporated (Nasdaq: VPHM) announced the publication of results of its previously described Phase 2 study showing that maribavir, when used as prophylaxis, reduced the rate of cytomegalovirus (CMV) reactivation and was well tolerated when compared to placebo in allogeneic stem cell, or bone marrow, transplant patients.

Read more...
View user's profileSend private message
Phase 2 Data Shows Maribavir Markedly Reduced Rate Of Cytom
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Stem Cell Research News
 Reply to topic  
Forum Map
Site Map